 SYDNEY, AUSTRALIA, Sept. 26, 2022 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, and Deanne Miller, COO, will participate in two upcoming investor conferences. 